SGMO — Sangamo Therapeutics, Inc.

SGMO Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Sangamo Therapeutics raised over $130 million in funding during 2025 through nondilutive license fees, milestone payments, and equity financing.
• The company is managing its cash carefully to extend its runway while seeking a commercial partner for its Fabry disease program.

2. Strategic Updates and Business Highlights:

• Positive top-line results from the STAAR study in Fabry disease were announced, with a favorable eGFR slope at 52 weeks, which the FDA indicated could support accelerated approval.
• A rolling submission for the Biologics License Application (BLA) for ST-920 is underway, with both nonclinical and clinical modules submitted, and the companion diagnostic accepted by the FDA.
• Sangamo transitioned to a clinical-stage neurology company, activating six clinical sites for the Phase I/II STAND study in chronic neuropathic pain.
• The company received Fast Track designation from the FDA for ST-503, aimed at treating small fiber neuropathy (SFN).
• A third licensing agreement for neurotropic capsids was established with Eli Lilly.

3. Forward Guidance and Outlook:

• The completion of the chemistry, manufacturing, and controls (CMC) module is the next key milestone for the BLA submission, anticipated to be completed by summer 2026, contingent on securing additional funding.
• The company remains focused on securing a commercial partner for the Fabry program, which is considered a top priority.

4. Bad News, Challenges, or Points of Concern:

• The timeline for the BLA submission has been extended primarily due to CMC activities, which are critical for cell and gene therapies and often challenging.
• Ongoing regulatory uncertainties and the complexity of securing partnerships have delayed discussions with potential partners, with many previous counterparties dropping out due to these uncertainties.
• The company is under pressure to manage its cash effectively while navigating these challenges.

5. Notable Q&A Insights:

• CEO Sandy Macrae emphasized that CMC activities are on the critical path for the BLA submission and that they are following FDA guidance closely.
• The company is currently in discussions with new partners for the Fabry program, as previous discussions have concluded due to regulatory concerns.
• The choice of AAV9 for the neuropathic pain program was based on historical effectiveness and safety, initiated before the development of the STAC-BBB capsid.

Overall, Sangamo Therapeutics is making progress in its pipeline, particularly with its Fabry disease program, but faces challenges in regulatory navigation and partnership discussions that could impact its financial stability and operational timelines.